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Background and Purpose: β-Arrestin2 recruitment to μ-receptors may contribute to
the development of opioid side effects. This possibility led to the development of
TRV130 and PZM21, opioids reportedly biased against β-arrestin2 recruitment in
favour of G-protein signalling. However, low efficacy β-arrestin2 recruitment by
TRV130 and PZM21 may simply reflect partial agonism overlooked due to
overexpression of μ-receptors.
Experimental Approach: Efficacies and apparent potencies of DAMGO, morphine,
PZM21 and TRV130 as stimulators of β-arrestin2 recruitment and inhibitors of cAMP
accumulation were assessed in CHO cells stably expressing μ-receptors. Receptor
availability was depleted through prior exposure of cells to the irreversible
antagonist, β-FNA. We also examined whether μ-receptor availability influences
TRV130 anti-nociception and/or tolerance using the tail withdrawal assay in
wild-type C57BL/6 and μ+/− mice.
Key Results: Morphine, PZM21 and TRV130 were partial agonists in the β-arrestin2
recruitment assay. Only TRV130 exhibited partial agonism in the cAMP assay.
Exposure to β-FNA to reduce μ-receptor availability further limited the efficacy of
TRV130 and revealed morphine and PZM21 to be partial agonists. Despite having
partial efficacy in vitro, TRV130 caused potent anti-nociception (ED50: 0.33 mgkg−1)
in wild-type mice, without tolerance after daily administration for 10 days. TRV130
caused similar anti-nociception in μ+/− mice, with marked tolerance on day 4 of
injections.
Conclusion and Implications: Our findings emphasise the importance of receptor
reserve when characterising μ-receptor agonists. Reduced receptor availability
reveals that TRV130 is a partial agonist capable of tolerance, despite having limited
efficacy for β-arrestin2 recruitment to the μ-receptor.
Abbreviations: DAMGO, [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin; GIRK, G protein-coupled inwardly rectifying K+ channels; GRK, GPCR kinase; MPE, maximum possible effect; ORL-1, opioid
receptor like-1; RLU, relative luminescence units; VACC, voltage-activated Ca2+ channel; WT, wild-type; β-FNA, β-funaltrexamine.
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1 | INTRODUCTION
Opioids, such as the prototypical drug morphine, are currently the
most effective analgesics combating short-term severe pain, but their
chronic use is compromised by the development of side effects
including tolerance, respiratory depression, constipation and
hyperalgesia (Colvin et al., 2019). Additionally, opioid-induced eupho-
ria and physical dependence contribute to their potential for addiction
and diversion towards illicit use. The development of new analgesics
that are devoid of detrimental side effects remains a challenge for
adequate long-term pain management (Yekkirala et al., 2017).
Opioids activate μ-receptors, GPCRs that mediate their analgesic
and their detrimental effects (Matthes et al., 1996). Activated μ-receptors
signal through Gαi/o proteins to inhibit adenylyl cyclase activity and
reduce cAMP accumulation. Activation of inwardly rectifying K+
channels (GIRK) and inhibition of voltage-activated Ca2+ channels
(VACCs) by the β subunits suppresses neuronal excitatory transmis-
sion leading to anti-nociception and analgesia (Heinke et al., 2011;
Nockemann et al., 2013).
Activated μ-receptors also become phosphorylated by
GPCR kinases (GRKs) leading to the recruitment of β-arrestin2.
This initiates μ-receptor desensitisation, internalisation and recycling
(Williams et al., 2013). Early evidence from knockout (Arrb2−/−) mice
implicated recruitment of β-arrestin2 in the development of opioid
side effects including constipation, respiratory depression and toler-
ance (Bohn et al., 1999; Bohn et al., 2000; Raehal et al., 2005). While
a subsequent study verified the need for β-arrestin2 for morphine tol-
erance (Bull, Baptista-Hon, Sneddon, et al., 2017), respiratory depres-
sion by morphine and fentanyl was recently observed in β-arrestin2
knockout mice (Kliewer et al., 2020). Furthermore, a conditional
knock-in mouse model in which μ-receptors are deficient in
phosphorylation by GRKs and therefore incapable of β-arrestin2
recruitment, exhibited morphine respiratory depression and constipa-
tion, with negligible tolerance (Kliewer et al., 2019). These findings
confirm that β-arrestin2 recruitment to the μ-receptor is crucial for
analgesic tolerance.
Evidence for the role of β-arrestin2 recruitment in the adverse
effects of opioids led to the search for μ-receptor agonists biased
in favour of G-protein signalling (Raehal et al., 2005). Recently,
PZM21 and TRV130 (oliceridine), opioids reported to be
biased towards G-protein activation with negligible β-arrestin2
recruitment were developed (Chen et al., 2013; Manglik et al., 2016).
These agonists reportedly exhibit fewer side effects compared to
morphine (DeWire et al., 2013; Manglik et al., 2016). However, recent
evidence suggests that PZM21 and TRV130 are partial agonists
(Yudin & Rohacs, 2019), a property that may account for the
potentially superior side effect profiles of these analgesics
(Gillis et al., 2020).
Limited efficacy of PZM21 and TRV130 may have been over-
looked in the original studies due to substantial receptor reserve in
assays in which μ-receptors were overexpressed (Kelly, 2013). Partial
agonists may display full efficacy in G protein-mediated inhibition of
cAMP accumulation, in which there is amplification, while having
negligible efficacy to recruit β-arrestin2, in which there is little or no
amplification (Baptista-Hon et al., 2020).
In this study, we tested the hypothesis that partial agonism of
reportedly biased agonists was previously overlooked in some studies
due to receptor reserve. We determined the relative efficacies and
apparent potencies of μ-receptor agonists DAMGO, morphine,
TRV130 and PZM21 as stimulators of β-arrestin2 recruitment and
inhibitors of cAMP accumulation in CHO cells with full or partial
μ-receptor availability after exposure to the irreversible antagonist
β-funaltrexamine (β-FNA). We also investigated whether TRV130,
recently approved for clinical use (U.S. Food and Drug
Administration, 2020), causes anti-nociceptive tolerance when admin-
istered to C57BL/6 mice and μ+/− mice that have a 50% reduction in
μ-receptor expression (Matthes et al., 1996).
2 | METHODS
2.1 | Cell culture
PathHunter CHO cells (DiscoverX, UK; RRID:CVCL_KY70) stably
overexpressing β-galactosidase tagged human μ-receptors and
What is already known
• Partial agonism may account for the favourable side-
effect profiles of reportedly biased μ agonists.
What this study adds
• Reducing receptor availability exposed partial agonism in
cAMP assays and TRV130 anti-nociceptive tolerance
in vivo.
What is the clinical significance
• TRV130 is capable of tolerance despite being a partial
agonist.
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β-arrestin2 were used in this study to assess cAMP accumulation and
β-arrestin2 recruitment in the same cell line expressing similar
numbers of receptors. Cells were maintained in complete media
composed of 1:1 DMEM/Ham's F12 + GlutaMAX™ (Gibco, UK), sup-
plemented with 10% FBS, penicillin (5,000 Uml−1), and streptomycin
(5,000 μgml−1). The selection agents geneticin (500 μgml−1) and
hygromycin B (250 μgml−1) were added to maintain stable expression
of μ-receptors and β-arrestin2 throughout. Cells were cultured at
37C in 5% CO2 and routinely subcultured when they reached
80% confluence.
2.2 | Transfection
Cells were plated in complete media for transfection in 35-mm culture
dishes at a density of 1 × 106 cells per dish. The following day, 2 μg of
pGloSensor-22F cDNA (Promega, UK) was transfected into each dish
using Lipofectamine 2000 at a 1:2.5 ratio (Invitrogen, UK) and left for
at least 16 h. Successful transfection was verified using a parallel dish
transfected with 2-μg pEGFP cDNA under the same conditions and
visualised using fluorescence microscopy.
2.3 | β-Arrestin2 recruitment
The PathHunter enzyme fragment complementation assay
(DiscoverX, UK) was used to assess β-arrestin2 recruitment to
μ-receptors according to the manufacturer's specification. CHO
cells were suspended in Opti-MEM (Gibco) and seeded onto a
96 half-well plate at a density of 5 × 103 cells per well and left to
settle overnight. Agonists were prepared in Opti-MEM (at 10×
concentrations) and diluted into the wells. Cells were incubated
with agonists for 90 min at 37C. The DiscoverX chemilumines-
cence substrate solution was added to each well and incubated for
2 h at room temperature in the dark. Luminescence was measured
on a GloMAX Navigator luminometer (Promega, UK) using a 1-s
integration time.
2.4 | cAMP accumulation
In parallel with β-arrestin2 recruitment experiments, inhibition of
forskolin-stimulated cAMP accumulation was measured in the
PathHunter CHO cells. Cells transfected with pGloSensor-22F were
suspended in complete media and seeded onto a 96 half-well plate at
a density of 1.5 × 104 cells per well and left to settle overnight
(according to the manufacturer's specification). Complete media were
replaced with assay buffer containing HBSS supplemented with
20-mM HEPES, 3-mM luciferin (Promega, UK) and 30-μM forskolin
(HelloBio, UK) at pH 7.4. Cells were left to incubate for 2 h at room
temperature in the dark before control luminescence was measured
on a GloMAX Navigator at 1-s integration time. Agonists (at 10× con-
centration) were prepared in assay buffer and diluted into the wells
and left to incubate for 30 min at room temperature in the dark. A
second luminescence reading was obtained at the end of agonist
incubation.
2.5 | Reducing available receptors using β-FNA
The number of available μ-receptors was reduced using the irrevers-
ible antagonist β-FNA to assess the efficacy and potency for
β-arrestin2 recruitment and inhibition of cAMP accumulation. For
β-arrestin2 recruitment, CHO cells were incubated with β-FNA
(diluted in Opti-MEM) for 1 h at 37C. β-FNA was removed and the
cells were washed twice with Opti-MEM before agonist addition. For
the cAMP accumulation assay, the method above was followed, with
the exception that the assay buffer was replaced with one which con-
tained β-FNA after 15 min and incubated for 1 h at 37C. β-FNA was
removed and cells were immediately washed with assay buffer and
left to recover for 15 min at room temperature. The assay buffer was
replaced again and incubated for a further 30 min before the control
luminescence was measured. Agonist addition and subsequent
measurements were performed as described above.
2.6 | Animals
Wild-type (WT) and μ+/− mice of both sexes weighing 19–29 g and
maintained on the C57BL/6J background were used to assess
TRV130 anti-nociception. All mice were aged between 8 and
16 weeks and housed in the University of Dundee School of Medicine
Resource Unit. Heterozygous μ+/− mice were generated by breeding
WT C57BL/6J (RRID:IMSR_JAX:000664) and μ−/− (RRID:
IMSR_JAX:007559) mice as previously described (Bull, Baptista-Hon,
Lambert, et al., 2017). Genotypes were confirmed at the end of the
experiment using the automated genotyping service provided by
Transnetyx (Cordova, USA). Groups were matched to age and sex,
with equivalent numbers coming from each cage where possible. Mice
were kept in a temperature-controlled room maintained at 19–21C
with a 12-h light–dark cycle and free access to food and water.
Behavioural experiments took place in the light phase at the same
time each day. Mice were handled and habituated to restraint for
3 days prior to starting behavioural experiments. Animal procedures
were performed in accordance with the UK Animals (Scientific
Procedures) Act 1986 and approved by the animal welfare and ethical
committee at the University of Dundee. Animal studies are reported
in compliance with the ARRIVE guidelines (Percie du Sert et al., 2020)
and with the recommendations made by the British Journal of
Pharmacology (Lilley et al., 2020).
2.7 | Materials
PathHunter CHO cells and proprietary assay buffer used for
chemiluminescence were purchased from DiscoverX (California, USA).
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Luciferin K+ salt and pGloSensor-22F cDNA were purchased from
Promega (Southampton, U.K). All cell culture and assay buffer
reagents used originate from Gibco and were purchased from Thermo
Fisher Scientific (Loughborough, U.K). DAMGO ([D-Ala2, NMe-Phe4,
Gly-ol5]-enkephalin; HelloBio), morphine (Sigma, UK), PZM21
(Cambridge Bioscience, UK), TRV130 (Generon, UK) and β-FNA
(Tocris, UK) were prepared as 10-mM stock solutions in either water
(morphine) or DMSO (DAMGO, PZM21, TRV130 and β-FNA).
2.8 | Drug administration
TRV130 (25-mgml−1 stock prepared in DMSO) was reconstituted
daily in 0.9% normal saline to a final concentration of 1 mgml−1 then
filtered using a 0.2-μm syringe. All injections were administered
subcutaneous into the scruff of the neck and dosed according to
individual body weights.
2.9 | Anti-nociception
TRV130 anti-nociception was assessed in vivo using a tail
withdrawal assay as previously described (Bull, Baptista-Hon,
Sneddon, et al., 2017). Each mouse had the distal third of their tail
placed into hot (48C) water and the latency to withdraw was
measured prior to and 30 min after, TRV130. Tails were submerged
up to a maximum of 15 s to prevent tissue damage. All latencies were
recorded with genotype and drug injection blinded.
2.10 | Tolerance
Dose–response relationships were determined on Day 1 and Day
10 by administering each mouse with escalating (0.01–10 mgkg−1)
doses of TRV130. Withdrawal latencies were measured as described
above following administration of each cumulative dose. For repeated
administration, TRV130 was administered once per day at a dose of
3.2 mgkg−1. This was determined to be the minimum dose required
to cause all mice to reach the maximum cut-off latency, when
assessed during the initial dose–response on Day 1. Tolerance was
assessed in WT and μ+/− mice by comparing the maximum possible
effect (MPE; see Section 2.11) of TRV130 on consecutive days of
testing.
2.11 | Data analysis
Luminescence values derived from β-arrestin2 recruitment assays are
expressed as a percentage of maximum luminescence (relative
luminescence units [RLU]) produced on each plate. Luminescence
values derived from cAMP accumulation assays are expressed as a
percentage of forskolin-stimulated cAMP concentration before the
addition of agonist. Luminescence values after exposure to β-FNA are
expressed as the percentage of the maximum luminescence produced
in the presence of the agonist without prior exposure to β-FNA.
Efficacy and potency data are compared to values evoked by DAMGO
in all cases in vitro, with the exception of β-FNA concentration–
response relationships, which are compared to the maximum control
response of each agonist. Concentration–response relationships were




1+10 ðLogEC50− Agonist½ ð Þ×Hill SlopeÞ
  ,
where apparent potency (EC50 or IC50), Hill slope and maximum
and minimum parameters were derived. Each dataset, derived from
luminescence values from individual plates, was fitted with the
above logistics function. Efficacy was measured as the difference
between minimum and maximum values of the fitted data. Potency
data were transformed into pEC50 or pIC50 values using the log
EC50 or IC50 multiplied by -1. Constraints to individual fits were
set to minimum ≥0 for β-arrestin2 recruitment and for cAMP accu-
mulation assays. One β-arrestin2 assay replicate was excluded from
final analysis and presentation because the associated Hill slope
values differed significantly from the other datasets. Averaged
concentration–response relationships were also fitted with the
logistics function and these are shown in the figures for illustrative
purposes only.
TRV130 anti-nociception in vivo is presented as the percentage





where baseline and drug latency represent the time to withdraw (s) in
the absence and presence of TRV130 respectively. ED50 values for
each animal were derived from the logistics function of individual
dose–response relationships fitted while constraining maximum to
≤100%. Averaged dose–response relationships were also fitted with
the logistics function and these are shown in the figure for illustrative
purposes only.
2.12 | Statistics
Analysed data were imported into GraphPad Prism software Version
8.4.1 (RRID:SCR_002798) for statistical analysis. The normality and
homogeneity of variance for datasets were confirmed. Sphericity was
also confirmed prior to performing a mixed ANOVA. Data satisfying
parametric assumptions were compared using a one-way or mixed
ANOVA, or t test as appropriate. Data not satisfying these
assumptions, even after transformation, were compared using the
Kruskal–Wallis test. Data derived from fitting individual experiments
are presented as mean ± SEM or with 95% confidence intervals (CIs).
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Fits to the averaged data in the figures are purely for illustrative pur-
poses and the derived values were not used for statistical compari-
sons. In all cases, group sizes are the number of independent values
and statistical comparisons were only performed on these values
where n > 5. Sample sizes in vivo were determined in G*Power using
our previous data assessing morphine anti-nociception and tolerance
in μ+/− mice (Bull, Baptista-Hon, Sneddon, et al., 2017). Given the
lack of previous literature examining the sex dependent effects of
TRV130 anti-nociception, these were examined separately in groups
of male and female mice. Differences were considered statistically
significant when P < .05. Pairwise comparisons were performed with
Bonferroni or Dunn's correction applied. The data and statistical
analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology
(Curtis et al., 2018). We have followed the recommendations set out
in the British Journal of Pharmacology editorials where they are
relevant.
2.13 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY
http://www.guidetopharmacology.org and are permanently archived
in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander
et al., 2019).
3 | RESULTS
3.1 | PZM21 and TRV130 evoke negligible
β-arrestin2 recruitment to μ-receptors
We used PathHunter CHO cells stably overexpressing human
μ-receptors to assess β-arrestin2 recruitment to μ-receptors.
Concentration–response relationships for DAMGO, morphine,
PZM21 and TRV130 are plotted in Figure 1a. Mean efficacy and
potency values derived from individual replicates are shown in Table 1.
Morphine, PZM21 and TRV130 were significantly less efficacious than
DAMGO as stimulators of β-arrestin2 recruitment. In terms of potency,
there were no significant differences between DAMGO, morphine,
PZM21 or TRV130 as stimulators of β-arrestin2 recruitment.
We next investigated the ability of PZM21 or TRV130 to
antagonise DAMGO-mediated β-arrestin2 recruitment, as would be
expected if they are competing for the DAMGO binding site and
acting as partial agonists. Concentration–response relationships of
PZM21 and TRV130 in the presence of 3-μM DAMGO are plotted
in Figure 1b. Our data show that both PZM21 and TRV130
F IGURE 1 β-Arrestin2 recruitment to μ-receptors. (a) Concentration–response relationships of DAMGO, morphine, PZM21 and TRV130 for
β-arrestin2 recruitment. Data from individual replicates were plotted and fitted with logistics functions to derive efficacy and potency parameters,
presented in Table 1. Data are expressed as a percentage of maximum relative luminescence units (RLU) produced on each plate. All experiments
were performed in duplicate with individual symbols showing mean ± SEM, n = 15 (DAMGO), n = 17 (morphine), n = 9 (PZM21) and n = 10
(TRV130). One plate (n = 1) was excluded from data analysis and presentation (see Section 2). (b) DAMGO-evoked β-arrestin2 recruitment was
inhibited in a concentration-dependent manner by either PZM21 or TRV130 co-application (0.0003–30 μM). Data are expressed as a percentage
of DAMGO (3 μM)-evoked recruitment on the same plate. All experiments were performed in duplicate. Data are shown as mean ± SEM, n = 8
for each agonist
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inhibited the ability of DAMGO to recruit β-arrestin2 in a
concentration-dependent manner. A logistics function fitted to
individual replicates revealed the mean IC50 values (with CIs) of
PZM21 and TRV130 to be 0.23 μM (0.09, 0.59 μM) and 0.25 μM
(0.13, 0.47 μM), respectively, suggesting that both PZM21 and
TRV130 bind to the same site as DAMGO but possess little
efficacy to recruit β-arrestin2.
3.2 | TRV130 displays partial efficacy as an
inhibitor of intracellular cAMP accumulation
We used PathHunter CHO cells, transiently transfected to express
the GloSensor protein, to assess changes in intracellular cAMP accu-
mulation as a consequence of μ-receptor activation. Concentration–
response relationships of DAMGO, morphine, PZM21 and TRV130
are plotted in Figure 2. Mean efficacy and apparent potency values
derived from individual replicates are shown in Table 2. The efficacy
of TRV130 was significantly less than that of DAMGO, demonstrat-
ing that TRV130 is a partial agonist in the cAMP accumulation
assay. Comparisons of the apparent potency values of these
agonists also revealed morphine and PZM21 to be less potent than
DAMGO, whereas the potency of TRV130 was similar to that of
DAMGO.
3.3 | Stimulation of β-arrestin2 recruitment by
DAMGO is more sensitive to depletion of available
μ-receptors than inhibition of cAMP
A previous report (Spivak et al., 2003) suggests that, under certain
conditions, β-FNA behaves as a partial μ agonist. Therefore, we
assessed the ability of β-FNA to recruit β-arrestin2 or inhibit cAMP
accumulation in CHO cells in the absence of agonists. CHO cells were
exposed to β-FNA (up to 100 μM) for 1 h and then unbound β-FNA
was washed off, after which the protocols above for measuring
β-arrestin2 recruitment or inhibition of cAMP accumulation were per-
formed in the absence of agonist. β-FNA failed to recruit β-arrestin2
(n = 4) or elicit a change in intracellular cAMP accumulation (n = 9;
data not shown).
We investigated the ability of DAMGO to recruit β-arrestin2 or
inhibit cAMP accumulation, while the number of available μ-receptors
was reduced following exposure to the irreversible μ-receptor antago-
nist, β-FNA. CHO cells were exposed to β-FNA for 1 h and then
unbound β-FNA was washed off prior to the addition of agonists.
F IGURE 2 μ-Receptor activation inhibits cAMP accumulation.
Concentration–response relationships of DAMGO, morphine, PZM21
and TRV130 as inhibitors of cAMP accumulation in PathHunter CHO
cells transiently expressing the pGloSensor-22F protein. Data from
individual replicates were plotted and fitted with logistics functions to
derive efficacy and potency parameters, presented in Table 2. Data
are expressed as a percentage of forskolin (30 μM)-stimulated
luminescence before the addition of agonists. All experiments were
performed in duplicate. Data are shown as mean ± SEM, n = 14
(DAMGO), n = 10 (morphine) and n = 9 (PZM21 and TRV130)
TABLE 1 Efficacies and potencies of
μ-receptor agonists as stimulators of
β-arrestin2 recruitment
Agonist % max RLU EC50 (nM) pEC50 Hill slope n
DAMGO 78 ± 3 208 (92, 325) 7 (6.6, 7.3) 1 ± 0.1 15
Morphine 26 ± 2* 195 (114, 276) 6.9 (6.6, 7.1) 1.4 ± 0.2 17
PZM21 4 ± 1* 183 (8, 359) 7.1 (6.6, 7.7) 1.7 ± 0.3 9
TRV130 5 ± 1* 139 (34, 244) 7.1 (6.7, 7.4) 1.6 ± 0.2 10
Note: Concentration–response relationships were plotted and fitted using a logistics function to yield
efficacy and potency values as stimulators of β-arrestin2 recruitment. A one-way ANOVA detected a
significant difference in mean efficacies (F3,47 = 174.8, P < .05). A one-way ANOVA revealed no
significant difference in potencies (F3,47 = 0.99, P > .05). Efficacy and Hill slope values are presented as
mean ± SEM and potency data are presented as mean with 95% confidence.
*Post hoc pairwise comparisons with Dunn's correction revealed morphine, PZM21 and TRV130 to be
significantly less efficacious compared to DAMGO (P < .05).
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TABLE 2 Efficacies and potencies of μ-receptor agonists as inhibitors of cAMP accumulation following receptor depletion
Agonist [β-FNA] (nM) cAMP (% forskolin max) IC50 (nM) pIC50 Hill slope n
DAMGO 0 64 ± 4 5 (1, 9) 8.5 (8.3, 8.8) 1 ± 0.1 14
10 54 ± 4 14 (3, 24) 8 (7.6, 8.4)d 1.3 ± 0.3 6
100 59 ± 9 112 (74, 150) 7 (6.8, 7.1)d 1 ± 0.1 8
Morphine 0 71 ± 4 13 (6, 21) 8 (7.7, 8.3)c 0.9 ± 0.1 10
10 56 ± 2 69 (31, 107) 7.2 (7, 7.5)d 1.1 ± 0.2 6
100 36 ± 4b 225 (55, 395) 6.8 (6.4, 7.2)d 1.6 ± 0.3 8
PZM21 0 51 ± 4 16 (3, 29) 8 (7.6, 8.4)c 1 ± 0.2 9
10 39 ± 5 41 (1, 85) 7.6 (7.1, 8) 1 ± 0.3 6
100 36 ± 4b 504 (33, 976) 6.5 (6.1, 6.8)d 0.9 ± 0.3 7
TRV130 0 45 ± 4a 9 (1, 20) 8.4 (8, 8.8) 1 ± 0.2 9
10 30 ± 4b 52 (17, 87) 7.4 (7, 7.7)d 0.8 ± 0.2 6
100 20 ± 2b 141 (28, 254) 7 (6.7, 7.4)d 1.7 ± 0.5 7
Note: Concentration–response relationships were plotted and fitted using the logistics function to yield efficacy and potency values for μ agonists as
inhibitors of cAMP accumulation with full (control) or partial μ-receptor availability following exposure to 10- or 100-nM β-FNA. A one-way ANOVA was
used to compare mean efficacies (F3,38 = 7.49, P < .05). The efficacy of DAMGO was not significantly different from control (F2,25 = 0.89, P > .05). A one-
way ANOVA was used to compare potencies (F3,38 = 3.4, P < .05). All experiments performed in duplicate. Efficacy and Hill slope presented as
mean ± SEM and potency data are presented as mean with 95% confidence.
aTRV130 had lower efficacy for cAMP inhibition compared to DAMGO without prior exposure to β-FNA (P < .05).
bCompared to control (0 nM), exposure to 10-nM β-FNA reduced the efficacy of TRV130 to inhibit cAMP accumulation and exposure to 100-nM β-FNA
reduced the efficacies of morphine, PZM21 and TRV130 (P < .05).
cPost hoc pairwise comparisons with Dunn's correction revealed morphine and PZM21 to be less potent than DAMGO for cAMP inhibition without prior
exposure to β-FNA (P < .05).
dPairwise comparisons also revealed that, compared to control (0 nM), exposure to 10-nM β-FNA reduced the potency of DAMGO, morphine and TRV130
and exposure to 100-nM β-FNA reduced the potency of all agonists (P < .05).
F IGURE 3 β-FNA causes irreversible, concentration-dependent antagonism of μ-receptor agonist-evoked signalling. (a) DAMGO-stimulated
β-arrestin2 recruitment (circles) and cAMP inhibition (squares) following exposure to increasing concentrations of β-FNA. Data are expressed as a
percentage of DAMGO (3 μM) response. A one-way ANOVA was performed to determine the concentration of β-FNA that first caused a
significant decrease in DAMGO-evoked response, in either the β-arrestin2 recruitment (F11,115 = 76.02, P < .05) or cAMP inhibition assay
(F11,119 = 51.14, P < .05). Post hoc pairwise comparisons with Dunn's correction revealed the first significant decreases to occur at 0.03-nM
β-FNA for β-arrestin2 recruitment (*P < .05) and 300-nM β-FNA for cAMP inhibition (#P < .05), n = 13 (β-arrestin2 recruitment) and n = 11 (cAMP
accumulation). (b) The same approach was used to determine the concentration of β-FNA to cause the first significant decrease in 3-μM morphine
(F11,115 = 45.97, P < .05), PZM21 (F14,119 = 11.96, P < .05), or TRV130 (F14,117 = 11.61, P < .05)-evoked inhibition of cAMP accumulation. Post
hoc pairwise comparisons with Dunn's correction revealed the first significant decreases to occur at 100 nM for morphine, 30 nM for PZM21 and
10 nM for TRV130 (#P < .05). All experiments performed in duplicate. Data fitted individually are shown as mean ± SEM, n = 11 (morphine) and
n = 12 (PZM21 and TRV130)
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Concentration–response relationships for β-FNA are plotted with a
logistics function fitted to the data shown in Figure 3a. Data were
expressed as the percentage of the maximum response produced by
DAMGO (3 μM) without prior exposure to β-FNA.
We determined the concentration of β-FNA required to produce
the first significant reduction in the ability of DAMGO to recruit
β-arrestin2 or inhibit cAMP accumulation using a one-way ANOVA
across all concentrations tested. Post hoc pairwise comparisons with
Dunn's correction revealed that the first significant reduction in the
maximal DAMGO stimulation of β-arrestin2 recruitment occurred
after exposure to 0.03-nM β-FNA. By contrast, the first significant
reduction from maximal DAMGO-evoked inhibition of cAMP accumu-
lation occurred after exposure to 300-nM β-FNA (Figure 3a). These
data reveal a remarkable difference in the sensitivity to receptor
availability of DAMGO's abilities to cause β-arrestin2 recruitment and
inhibition of cAMP.
We used the same approach to determine the minimum concen-
tration of β-FNA required to reduce the maximum inhibition of cAMP
accumulation by morphine, PZM21 or TRV130. All agonists were
applied at 3 μM, which produces maximum inhibition of cAMP accu-
mulation (Figure 2). Concentration–response relationships for β-FNA
are shown in Figure 3b. Post hoc pairwise comparisons revealed the
concentrations of β-FNA required to produce the first significant
reduction in maximum cAMP inhibition to be: 100 nM for morphine,
30 nM for PZM21,and 10 nM for TRV130 (Figure 3b). These data are
consistent with the rank order of efficacies for these partial agonists
being morphine > PZM21 > TRV130.
3.4 | The potency of β-arrestin2 recruitment by
DAMGO is unaffected by irreversible μ-receptor
antagonism
We used the same approach to investigate the effect that μ-receptor
depletion has on the concentration–response relationship for
DAMGO to recruit β-arrestin2. The ability of DAMGO to stimulate
β-arrestin2 recruitment is abolished following exposure to concentra-
tions of β-FNA exceeding 10 nM in the β-arrestin2 recruitment assay.
Therefore, the number of available μ-receptors was reduced by expos-
ing the cells to 0-, 1- or 10-nM β-FNA as described. DAMGO
concentration–response relationships following exposure to these
concentrations of β-FNA are plotted in Figure 4. Mean efficacy and
potency values derived from individual replicates are shown in
Table 3.
As expected, exposure to β-FNA reduced the efficacy of
β-arrestin2 recruitment by DAMGO in a concentration-dependent
manner. However, the potency of DAMGO to stimulate β-arrestin2
recruitment following exposure to either 1- or 10-nM β-FNA was
not significantly different to the potency of DAMGO without
prior exposure to β-FNA. These data confirm that depletion of
μ-receptors in β-arrestin2 recruitment assays reduces the efficacy of
DAMGO to recruit β-arrestin2, while having little effect on agonist
potency.
3.5 | Partial agonism by morphine, PZM21 and
TRV130 emphasised by reducing the availability of
μ-receptors
Compared to the β-arrestin2 recruitment assay, exposure to higher
concentrations of β-FNA is required to reduce agonist efficacy in
cAMP accumulation assays. Therefore, we subsequently exposed
PathHunter CHO cells to either 10- or 100-nM β-FNA, to investigate
the effect that depletion of μ-receptor availability has on their
concentration–response relationships in the cAMP accumulation
assay. This approach allowed us to compare efficacies and apparent
potency values with increasingly restricted receptor reserve.
Concentration–response relationships of all four agonists are shown
in Figure 5. Mean efficacy and apparent potency values derived from
individual replicates are shown in Table 2.
We compared the efficacies of DAMGO, morphine, PZM21 and
TRV130 to inhibit cAMP accumulation following exposure to 10- or
100-nM β-FNA, to their efficacies to inhibit cAMP accumulation with-
out exposure to β-FNA. There was no significant difference detected
in the efficacy of DAMGO to evoke changes in cAMP accumulation




[β-FNA] (nM) % max RLU EC50 (nM) pEC50 Hill slope n
0 75 ± 2 275 (147, 402) 6.7 (6.4, 7) 1.3 ± 0.1 9
1 42 ± 5* 355 (164, 546) 6.6 (6.3, 6.8) 1.2 ± 0.1 9
10 19 ± 3* 263 (152, 374) 6.7 (6.4, 6.9) 1.7 ± 0.3 9
Note: Concentration–response relationships were plotted and fitted using a logistics function to yield
efficacy and potency values for DAMGO-evoked β-arrestin2 recruitment following exposure to
increasing concentrations of β-FNA. A Kruskal–Wallis test was used to compare efficacies (χ2(2) = 19.13,
P < .05). A one-way ANOVA detected no significant difference in mean potency values (F2,24 = 0.36,
P > .05). Efficacy and Hill slope values are presented as mean ± SEM and potency data are presented as
mean with 95% confidence.
*Post hoc pairwise comparisons with Dunn's correction revealed DAMGO to be significantly less
efficacious as a stimulator of β-arrestin2 recruitment following exposure to 1- or 10-nM β-FNA compared
to DAMGO without prior exposure (P < .05).
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efficacies of morphine, PZM21 and TRV130 were reduced following
exposure to 100-nM β-FNA. The efficacy of TRV130 was also
reduced following exposure to 10-nM β-FNA. These results confirm
that morphine, PZM21 and TRV130 are partial μ-receptor agonists.
3.6 | TRV130 produces potent anti-nociception
without evidence of tolerance in WT mice
We assessed TRV130 anti-nociception in vivo using a hot (48C)
water tail withdrawal assay in male and female C57Bl/6 mice. Opioid-
naïve mice were exposed to escalating doses of TRV130 (ranging from
0.01 to 10 mgkg−1) and the latencies to withdraw their tails were
measured and expressed as maximum possible effect (MPE, see
Section 2). Dose–response relationships of TRV130 in WT mice are
shown in Figure 6. Data are shown pooled for males and females after
determining that there was no significant difference in the potency of
TRV130 anti-nociception between sexes in WT mice (unpaired Stu-
dent's t-test). TRV130 caused potent anti-nociception with a mean
ED50 of 0.33 (0.21, 0.46) mgkg−1 when assessed on Day 1. Further-
more, TRV130 caused the maximum possible level of anti-nociception
in all mice at a cumulative dose of 3.2 mgkg−1 (Figure 6a).
After establishing that TRV130 evokes the maximal anti-
nociceptive effect in WT mice at a cumulative dose of 3.2 mgkg−1,
we then investigated whether tolerance occurred in the same mice
exposed daily to this dose for 10 days. We observed a small rightward
shift in the maximum possible effect of TRV130 after 10 days
(Figure 6a). However, TRV130 was equally potent on Day 10 with a
mean ED50 of 0.68 (0.23, 1.13) mgkg−1 (Figure 6b). Furthermore, the
baseline latency on Day 10 was not significantly different compared
to Day 1. These results confirm that the lack of observed tolerance in
WT mice is not due to altered baseline latencies.
3.7 | Reduced μ-receptor availability caused
TRV130 anti-nociceptive tolerance
We similarly assessed TRV130 anti-nociception in μ+/− mice, which
express 50% fewer receptors than WT mice (Matthes et al., 1996).
F IGURE 5 Partial agonism of morphine, PZM21 and TRV130 emphasised by reducing the availability of μ-receptors. Concentration–response
relationships of (a) DAMGO, (b) morphine, (c) PZM21 and (d) TRV130 to inhibit cAMP accumulation following exposure to 10- or 100-nM β-FNA.
Data from individual replicates were plotted and fitted with logistics functions to derive efficacy and potency parameters, shown in Table 2.
Concentration–response relationships in the absence of β-FNA are reproduced for comparison (dashed black lines)
F IGURE 4 DAMGO-evoked β-arrestin2 recruitment following
exposure to β-FNA. Concentration–response relationships of
DAMGO-evoked β-arrestin2 recruitment in PathHunter CHO cells
following exposure to 0-, 1-, or 10-nM β-FNA. Data from individual
replicates were plotted and fitted with logistics functions to derive
efficacy and potency parameters, presented in Table 3. Data are
expressed as a percentage of maximum relative luminescence units
(RLU) produced on each plate. All experiments performed in duplicate.
Data are shown as mean ± SEM, n = 9 per β-FNA concentration
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Dose–response relationships are shown in Figure 7. Data are pooled
for males and females after finding that there was no significant dif-
ference in the potency of TRV130 anti-nociception between sexes in
μ+/− mice (unpaired t test). TRV130 was similarly potent in μ+/− mice
with a mean ED50 of 0.44 (0.1, 0.84) mgkg−1. There was no signifi-
cant difference in potency between WT and μ+/− mice following
F IGURE 6 TRV130 causes potent anti-nociception without evidence of tolerance in C57Bl/6 mice. (a) Cumulative dose–response
relationships for TRV130 anti-nociception in WT mice administered with TRV130 acutely (Day 1) or following 10 consecutive days
(3.2 mgkg−1day−1). Data are expressed as the per cent maximum possible effect (MPE; see Section 2). (b) ED50 values on Day 1 (0.33 (0.21, 0.46)
mgkg−1) were not significantly different to Day 10 (0.68 (0.23, 1.13) mgkg−1; P > .05, paired Student's t-test). (c) Baseline latencies on Days
1 and 10 were not significantly different (P > .05, paired Student's t-test). Dose–response relationships from individual animals were plotted and
fitted with logistics functions to derive TRV130 potency. Data are shown as mean ± SEM, n = 9
F IGURE 7 Reduced μ-receptor number causes the appearance of TRV130 anti-nociceptive tolerance. (a) Cumulative dose–response
relationship for TRV130 anti-nociception in C57Bl/6 mice expressing 50% fewer μ-receptors (μ+/−) than WT mice. ED50 values in μ+/− mice
(0.44 (0.1, 0.84) mgkg−1), derived from logistics functions fitted to individual dose–response relationships, were not significantly different
compared to WT mice (P > .05, unpaired t test with Welch's correction). The logistic fit to the mean TRV130 dose–response relationship for WT
mice is reproduced for comparison. (b) TRV130 anti-nociception in WT and μ+/− mice receiving a 3.2-mgkg−1 dose for seven consecutive days.
A Kruskal–Wallis test comparing MPE in WT versus μ+/− mice detected a significant difference (χ2(13) = 98.12, P < .05). Post hoc pairwise
comparisons with Dunn's correction revealed μ+/− mice had significantly shorter withdrawal latencies than WT mice after 4 days (*P < .05).
(c) Baseline withdrawal latencies in WT and μ+/− mice across seven consecutive days of behavioural testing. A mixed-model ANOVA comparing
baseline latencies revealed no significant effect of genotype (F1,17 = 1.99, P > .05) or time (F6,102 = 0.64, P > .05). Data in (a) and (c) are shown as
mean ± SEM. Data in (b) are presented as median ± IQR, n = 9 (WT) and n = 10 (μ+/−)
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acute exposure (Figure 7a). Furthermore, the maximum level of
TRV130 anti-nociception was also produced in all μ+/− mice follow-
ing a cumulative dose of 3.2 mgkg−1.
We investigated the effect that reduced μ-receptor number had
on the development of anti-nociceptive tolerance to daily TRV130.
WT and μ+/− mice had their withdrawal latencies measured as
described above both before and 30 min after TRV130 (3.2 mgkg−1).
Maximum possible effect in WT and μ+/− mice repeated over seven
consecutive days is shown in Figure 7b. Pairwise comparisons with
the Bonferroni correction revealed that μ+/− mice had significantly
lower maximum possible effect compared to WT mice, after 4 days of
daily TRV130 administration. Our results demonstrate that reduced
availability of μ-receptors in vivo causes the appearance of anti-
nociceptive tolerance to TRV130.
Baseline withdrawal latencies in WT and μ+/− mice across seven
consecutive days of behavioural testing are shown in Figure 7c. No
significant effect of genotype was detected in baseline withdrawal
latencies between WT and μ+/− mice. These results confirm that the
reduction in maximum possible effect observed in μ+/− mice is not
due to altered baseline latencies.
4 | DISCUSSION
The results presented here confirm previous studies (DeWire
et al., 2013; Manglik et al., 2016) demonstrating that PZM21 and
TRV130 cause limited stimulation of β-arrestin2 recruitment to human
μ-receptors, while having higher efficacies as inhibitors of cAMP accu-
mulation. Importantly, our initial cAMP and β-arrestin2 recruitment
assays were performed in cells with the same μ-receptor density.
Under these conditions, TRV130, unlike the other agonists tested,
lacked full efficacy as an inhibitor of cAMP. However, when
μ-receptor availability was reduced by prior exposure to the irrevers-
ible μ-receptor antagonist β-FNA, morphine and PZM21 were also
revealed to be partial agonists in the cAMP assay with lower efficacies
than DAMGO. These findings suggest that partial agonism of report-
edly biased agonists was previously overlooked in some studies due
to receptor reserve.
Reduced receptor availability also decreased the apparent poten-
cies of all agonists as inhibitors of cAMP accumulation. By contrast,
reduced μ-receptor availability did not affect the potency of DAMGO
as a stimulator of β-arrestin2 recruitment, despite reduced efficacy.
The rank orders of the agonists' efficacies in the β-arrestin2 recruit-
ment and cAMP assays (the latter with reduced receptor availability)
were DAMGO > morphine > PZM21 = TRV130 and DAMGO >
morphine = PZM21 > TRV130 respectively.
Negligible recruitment of β-arrestin2 to human μ-receptors by
PZM21 and TRV130 may confer these agonists with favourable thera-
peutic properties. However, the benefits of poor β-arrestin2 recruit-
ment are the subject of debate. Recent evidence (Hill et al., 2018;
Kliewer et al., 2019; Kliewer et al., 2020) casts doubt on the interpre-
tation of an earlier study linking β-arrestin2 to opioid-induced respira-
tory depression and constipation (Raehal et al., 2005). By contrast,
morphine anti-nociceptive tolerance is consistently found to be
dependent on β-arrestin2 recruitment (Bohn et al., 2000; Bull,
Baptista-Hon, Sneddon, et al., 2017; Kliewer et al., 2019; Yang
et al., 2011). It is not surprising then that TRV130, which causes little
recruitment of β-arrestin2 in vitro, caused no anti-nociceptive toler-
ance when administered daily to WT mice for 10 days, a finding con-
sistent with previous reports (Altarifi et al., 2017; Liang et al., 2019).
However, when administered under the same conditions to μ+/−
mice, with 50% fewer receptors than WT mice (Matthes et al., 1996),
TRV130 caused marked anti-nociceptive tolerance after only 4 days.
We previously demonstrated that fewer available receptors also led
to more rapid and profound morphine analgesic tolerance (Bull,
Baptista-Hon, Sneddon, et al., 2017). The lack of tolerance to TRV130
in WT mice is likely due to the agonist's lower intrinsic efficacy, which
limits β-arrestin2 recruitment and downstream effects such as recep-
tor endocytosis. This, combined with substantial μ-receptor reserve,
enables robust anti-nociception without tolerance in WT mice. Recep-
tor reserve is evidenced by the fact that morphine and TRV130 also
cause full anti-nociception in μ+/− mice, despite these ligands being
partial μ-receptor agonists. It is important to note, however, that the
use of moderate heat and an exposure limit of 15 s in our study may
contribute to the appearance of full TRV130 efficacy in both WT and
μ+/− mice (Smith et al., 1999).
We had anticipated that, given its low efficacy in the β-arrestin2
recruitment assay, TRV130 would not exhibit anti-nociceptive toler-
ance and in keeping with previous studies (Altarifi et al., 2017; Liang
et al., 2019) this was true in the case of WT mice. However, robust
tolerance occurred in μ+/− mice. Perhaps limited TRV130-evoked
β-arrestin2 recruitment has a greater impact in μ+/− mice. However,
our findings with β-FNA demonstrate that even with the high-efficacy
agonist DAMGO, small reductions in μ-receptor availability cause
large reductions in β-arrestin2 recruitment. The observation that
TRV130 caused marked anti-nociceptive tolerance in μ+/− mice was
therefore unexpected. It was also surprising that tolerance to TRV130
was similar to that observed previously with morphine in μ+/− mice
(Bull, Baptista-Hon, Sneddon, et al., 2017), considering TRV130's
lower efficacy than morphine in vitro.
It is hard to reconcile the finding that relatively small reductions
in receptor availability impede β-arrestin2 recruitment in the cellular
assay, while a large reduction in receptor availability in vivo enhances
tolerance. This implies that there is a lack of a simple correlation
between β-arrestin2 recruitment and tolerance and may reduce the
likelihood of developing biased agonists that do not cause analgesic
tolerance.
The situation in vivo is of course more complex than in the
in vitro studies in which recombinant μ-receptors are overexpressed
in relatively simple cellular models. In particular, neurones in the pain
pathway and elsewhere in the brain often express more than one type
of opioid receptor. This may affect μ-receptor activity either through
the formation of heteromers or through signalling crosstalk (Charles
et al., 2003; Fujita et al., 2015). When expressed together, μ- and
δ-receptors recruit β-arrestin2 in the absence of agonist and this may
alter the pattern of agonist-evoked activation of kinases and
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agonist-evoked desensitisation (Bull, Baptista-Hon, Lambert,
et al., 2017; Rozenfeld & Devi, 2007). Indeed, mice lacking δ-receptors
exhibit negligible morphine anti-nociceptive tolerance (Zhu
et al., 1999). Furthermore, most μ-receptor agonists have activity at
other opioid receptors. For example, TRV130 is also a potent agonist
at δ- and κ-receptors (Gutridge et al., 2020; Manglik et al., 2016).
Therefore, other opioid receptors may contribute to TRV130 anti-
nociception and tolerance. Our finding that potency is similar in μ+/−
and WT mice is consistent with the idea that other receptors might
contribute to TRV130 anti-nociception.
It is important to consider additional limitations of the in vitro
assays used to compare G-protein signalling and β-arrestin2 recruit-
ment, which may also compromise the characterisation of opioids
and, in particular, estimates of agonist bias. In our study, both
assays were performed in the same cells stably expressing
μ-receptors and were therefore not unintentionally affected by
differences in receptor reserve, which might otherwise confound
comparisons of agonist efficacies. Nevertheless, it is clear that
reductions in μ-receptor availability had profoundly different impacts
on the two assays. Much more substantial β-FNA-evoked reductions
in μ-receptor availability were required to impair the efficacy of
DAMGO as an inhibitor of cAMP accumulation when compared to
DAMGO's stimulation of β-arrestin2 recruitment. This is consistent
with the idea that signalling to AC requires a small fraction of the
available μ-receptors compared to recruitment of β-arrestin2, due to
amplification in the former but not the latter (Baptista-Hon
et al., 2020). The cAMP assay provides a highly sensitive method
for the detection of the weakest agonists, while the β-arrestin2
recruitment assay yields a more accurate reflection of the relative
potencies and efficacies of agonists. While it is experimentally expe-
ditious to use simple cellular models for the identification of new
analgesic opioids, more comprehensive approaches are needed for
complete characterisation.
Interestingly, reductions in μ-receptor availability, insufficient to
depress DAMGO's efficacy in the cAMP assay, were associated with
decreased apparent potency. This was not the case in the β-arrestin2
recruitment assay in which DAMGO's efficacy declined without
altered potency. This is likely because signalling to AC does not repre-
sent a simple 1:1 stoichiometry between receptor and effector. In this
case, there is a contribution of agonist efficacy in the measurement of
apparent potency (Colquhoun, 1998).
Numerous studies in recent years have focused on the poten-
tial for biased signalling in the development of new analgesic
opioids including PZM21 and TRV130. However, our study
supports previous reports indicating that these new opioids are in
fact partial μ-receptor agonists, a property that potentially explains
their favourable side-effect profile (Gillis et al., 2020; Hill
et al., 2018). While these new opioids might prove to be useful, it
is unclear how they will be superior as analgesics to the existing
μ-receptor partial agonist buprenorphine. Buprenorphine has
additional potentially beneficial antagonist and agonist activities at
κ- and opioid receptor like-1 (ORL-1) receptors, respectively
(Lutfy & Cowan, 2004). There may also be a contribution of a
longer μ-receptor residence time for buprenorphine than TRV130
(Pedersen et al., 2020) and differences in the pharmacokinetic
profiles of the two opioids.
Our findings emphasise the need for consideration of receptor
availability when characterising μ-receptor agonists and important
insights that can be gained by taking measures to deplete receptor
reserve. We suggest that it should become common practice to
reduce receptor reserve during agonist characterisation to establish
the true efficacies of new ligands and, in particular, before assignation
of agonist bias.
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